Equity Overview
Price & Market Data
Price: $1.29
Daily Change: +$0.0012 / 0.09%
Range: $1.28 - $1.35
Market Cap: $24,702,144
Volume: 63,509
Performance Metrics
1 Week: 16.96%
1 Month: 12.93%
3 Months: -37.02%
6 Months: -17.09%
1 Year: 95.52%
YTD: -27.62%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.